Omid Hamid MD

Dr. Omid Hamid, MD, is the Chief of Translational Research and Immuno-Oncology at The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate. He serves as the Co-Director of the Melanoma and the Director of Phase I Programs. He is a Professor in the Department of Medicine at Cedars-Sinai and heads the Experimental Therapeutics division. His areas of expertise include Phase I drug development, cutaneous malignancies, Immuno-oncology, and Malignant Melanoma.

Dr. Hamid is recognized nationally and internationally as one of the pre-eminent immuno-oncologists and melanoma specialists in the world and has published extensively on and been at the forefront of paradigm-shifting breakthrough treatments, including Checkpoint Inhibitors (anti-CTLA4, anti-PD-1 therapies), BRAF/MEK and novel-targeted agents, antibody drug conjugates, and novel therapies. His current research interests include next-generation Immunotherapeutics, including novel immune-checkpoint inhibitors, bispecific antibodies, adoptive T cell therapies, CAR-T, and oncolytic therapies, with a focus on combinatorial approaches.